Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease.

ABSTRACT: Positive modulation of hepatocyte growth factor (HGF) signaling may represent a promising therapeutic strategy for Alzheimer's disease (AD) based on its multimodal neurotrophic, neuroprotective, and anti-inflammatory effects addressing the complex pathophysiology of neurodegeneration. Fosgonimeton is a small-molecule positive modulator of the HGF system that has demonstrated neurotrophic and pro-cognitive effects in preclinical models of dementia. Herein, we evaluate the neuroprotective potential of fosgonimeton, or its active metabolite, fosgo-AM, in amyloid-beta (Aβ)-driven preclinical models of AD, providing mechanistic insight into its mode of action. In primary rat cortical neurons challenged with Aβ (Aβ_1-42), fosgo-AM treatment significantly improved neuronal survival, pro

SUBMITTER: Reda SM 

PROVIDER: S-EPMC11067346 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature